Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: lane t. Leukemia. 2014 Dec;28(12):2304-10. doi: 10.1038/leu.2014.218. Epub 2014 Jul 16. Leukemia. 2014. PMID: 25027514
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: lane t. Blood. 2012 May 10;119(19):4387-90. doi: 10.1182/blood-2011-10-388462. Epub 2012 Feb 13. Blood. 2012. PMID: 22331187 Free article.
A prospective study of nutritional status in immunoglobulin light chain amyloidosis.
Sattianayagam PT, Lane T, Fox Z, Petrie A, Gibbs SD, Pinney JH, Risom SS, Rowczenio DM, Wechalekar AD, Lachmann HJ, Gilbertson JA, Hawkins PN, Gillmore JD. Sattianayagam PT, et al. Among authors: lane t. Haematologica. 2013 Jan;98(1):136-40. doi: 10.3324/haematol.2012.070359. Epub 2012 Sep 14. Haematologica. 2013. PMID: 22983575 Free PMC article.
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD. Venner CP, et al. Among authors: lane t. Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. Haematologica. 2014. PMID: 25193959 Free PMC article. No abstract available.
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD. Rezk T, et al. Among authors: lane t. Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18. Kidney Int. 2017. PMID: 28729034 Free article.
1,179 results